A new review has summarized three potential biomarkers of adverse effects that may occur with disease-modifying therapies used in the treatment of MS (Kreft et al. J Neurol 2022;269:5192-5193). (Free references below.) All results are preliminary and further validation is required.
Latest News
CLINICAL CASES IN MS – CASE 6: DIAGNOSTIC DILEMMA
August 22, 2022Click here to watch Dr. Virender Bhan discuss the case and the responses to the survey.
Joseph is a 28-year-old shipping manager at a local warehouse. He is married and has a three-year-old daughter. He presents in April 2021 following an episode of right sided vision loss, with minimal pain. Exam showed visual acuity 20/400, loss of colour vision and an afferent pupillary defect. The rest of his neuro exam is normal. Brain MRI revealed MS-like white-matter abnormalities with a moderate burden of disease and evidence of right optic neuritis (T2 hyperintensity and contrast enhancement). He was treated with IVMP 1000 mg daily x 3 days, with minimal improvement. There is no history of comorbid conditions and no family history of demyelinating or autoimmune disorders. He has not received a COVID-19 vaccine. Extensive discussion does not change his mind and he says he has no plans to get vaccinated. Read More
Is a cell-depleting DMT safe prior to HSCT?
August 9, 2022Long-acting disease-modifying therapies do not appear to increase the risk of complications following autologous hematopoietic stem cell transplantation (aHSCT), according to a retrospective study from Sweden (Kvistad et al. J Neurol Neurosurg Psychiatry 2022;93:844-848). Read More
COVID-19 and MS – updated findings
July 28, 2022The following is a summary of recent findings on COVID-related issues in patients with multiple sclerosis. Read More